Evidence map›Paper›PMID 41406955›Full record

ArticleJournal of medicinal chemistry2026

Discovery of AVI-6451, a Potent and Selective Inhibitor of the SARS-CoV-2 ADP-Ribosylhydrolase Mac1 with Oral Efficacy In Vivo.

Priyadarshini Jaishankar, Galen J Correy, Yusuke Matsui, Takaya Togo, Moira M Rachman, Maisie G V Stevens, Eric R Hantz, Jeffrey Zheng, Morgan E Diolaiti, Mauricio Montano and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Priyadarshini JaishankarDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.
Galen J CorreyDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.
Yusuke MatsuiGladstone Institute of Virology, Gladstone Institutes, 1650 Owens Street, San Francisco, California 94158, United States.
Takaya TogoDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.
Moira M RachmanDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.ORCID 0000-0003-3671-8885
Maisie G V StevensHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 1450 Third St., San Francisco, California 94158, United States.
Eric R HantzDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.ORCID 0000-0002-2588-7619
Jeffrey ZhengDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.ORCID 0000-0002-4691-9317
Morgan E DiolaitiHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 1450 Third St., San Francisco, California 94158, United States.ORCID 0000-0001-5900-3060
Mauricio MontanoGladstone Institute of Virology, Gladstone Institutes, 1650 Owens Street, San Francisco, California 94158, United States.
Taha Y TahaGladstone Institute of Virology, Gladstone Institutes, 1650 Owens Street, San Francisco, California 94158, United States.ORCID 0000-0002-7344-7490
Julia RosecransGladstone Institute of Virology, Gladstone Institutes, 1650 Owens Street, San Francisco, California 94158, United States.
Julius PampelDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.
Nevan J KroganDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.ORCID 0000-0003-4902-337X
Brian K ShoichetDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.ORCID 0000-0002-6098-7367
Alan AshworthHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 1450 Third St., San Francisco, California 94158, United States.
Melanie OttGladstone Institute of Virology, Gladstone Institutes, 1650 Owens Street, San Francisco, California 94158, United States.
James S FraserDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.ORCID 0000-0002-5080-2859
Adam R RensloDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.ORCID 0000-0002-1240-2846

Funding

Targeting Viroporins and Coronavirus M ProteinU19AI171110 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDREJ SALI · 2022 to 2026
$103.4M
A Synchrotron Radiation Structural Biology ResourcesP30GM133894 · NIGMS · STANFORD UNIVERSITY · PI Aina E. Cohen, KEITH O HODGSON · 2020 to 2026
$43.3M
User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI PAUL David ADAMS, Gregory L Hura · 2017 to 2026
$28.6M
Research Training in Chemistry and Chemical BiologyT32GM145460 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jason E Gestwicki · 2022 to 2026
$3.1M
NIAID NIH HHS U19 AI171110NIGMS NIH HHS P30 GM124169NIGMS NIH HHS P30 GM133894NIGMS NIH HHS T32 GM145460
6 · The paper itself

Abstract

The COVID-19 pandemic emphasized the need for effective antivirals acting at new targets. We recently described AVI-4206, a 9

Indexed as

Antiviral AgentsCOVID-19 Drug TreatmentEnzyme InhibitorsIndolesSARS-CoV-2Administration, OralAnimalsBiological AvailabilityCOVID-19Drug DiscoveryFemaleHumansMiceStructure-Activity RelationshipAntiviral AgentsEnzyme InhibitorsIndoles

Identifiers

PMID41406955
PMCPMC12788873

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.